Disseminated intravascular b-cell lymphoma: Clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy

Oncologist

Volumn 11, Issue 8, 2006, Pages 923-928

  Bouzani, Maria ^a   Karmiris, Themis ^a   Rontogianni, Dimitra ^a   Delimpassi, Susanna ^a   Apostolidis, John ^a   Mpakiri, Maria ^a   Nikiforakis, Emmanuel ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Extranodal lymphoma; Immunochemotherapy; Intravascular lymphoma

Indexed keywords

ANTHRACYCLINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; LAMIVUDINE; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; DISSEMINATED CANCER; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LABORATORY TEST; LYMPH NODE BIOPSY; MALE; NONHODGKIN LYMPHOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; SPLENECTOMY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 33748553701     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-8-923     Document Type: Article

References (25)

1. Bhawan J, Wolff SM, Ucci AA et al. Malignant lymphoma and malignant angioendotheliomatosis: one disease. Cancer 1985;55:570-576.
2. Sheibani K, Battifora H, Winberg CD et al. Further evidence that "malignant angioendotheliomatosis" is an angiotropic large-cell lymphoma. N Engl J Med 1986;314:943-948.
3. Carroll TJ Jr, Schelper RL, Goeken JA et al. Neoplastic angioendotheliomatosis: immunopathologic and morphologic evidence for intravascular malignant lymphomatosis. Am J Clin Pathol 1986;85:169-175.
4. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
5. Ferreri AJ, Campo E, Seymour JF et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 2004;127:173-183.
6. Wick MR, Mills SE. Intravascular lymphomatosis: clinicopathologic features and differential diagnosis. Semin Diagn Pathol 1991;8:91-101.
7. Glass J, Hochberg FH, Miller DC. Intravascular lymphomatosis. A systemic disease with neurologic manifestations. Cancer 1993;71:3156- 3164.
8. DiGiuseppe JA, Nelson WG, Seifter EJ et al. Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol 1994;12:2573-2579.
9. Stroup RM, Sheibani K, Moncada A et al. Angiotropic (intravascular) large cell lymphoma: a clinicopathologic study of seven cases with unique clinical presentations. Cancer 1990;66:1781-1788.
10. Fiegl M, Greil R, Pechlaner C et al. Intravascular large B-cell lymphoma with a fulminate clinical course: a case report with definite diagnosis post mortem. Ann Oncol 2002;13:1503-1506.
11. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
12. Ferreri AJ, Campo E, Ambrosetti A et al. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol 2004;15:1215-1221.
13. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
14. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
15. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol 2006;7:379-391.
16. Davis TS. Intravascular lymphoma presenting with cauda equine syndrome: treated with CHOP and rituxan. Leuk Lymphoma 2003;44:887-888.
17. Weichert G, Martinka M, Rivers JK. Intravascular lymphoma presenting as telangectasias: response to rituximab and combination chemotherapy. J Cutan Med Surg 2003;7:460-463.
18. Takacs I, Eros N, Bene I et al. Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy. Ann Hematol 2004;83:608-610.
19. Bazhenova L, Higginbottom P, Mason J. Intravascular lymphoma: a role for single-agent rituximab. Leuk Lymphoma 2006;47:337-341.
20. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
21. Turner NC, Dusheiko G, Jones A. Hepatitis C and B-cell lymphoma. Ann Oncol 2003;14:1341-1345.
22. Marcucci F, Mele A, Spada E et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006;91:554-557.
23. Lok ASF, Liang RHS, Chiu EKW et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
24. Skrabs C, Müller C, Agis H et al. Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 2002;16:1884-1886.
25. Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.